TCM
VRDN icon

TCG Crossover Management’s Viridian Therapeutics VRDN Stock Holding History

TCG Crossover Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-663,610
Closed -$16.9M – 23
2023
Q1 		$16.9M Sell
663,610
-320,000
-33% -$10.3M 3.29% 13
2022
Q4 		$28.7M Sell
983,610
-180,390
-15% -$4.16M 5.07% 8
2022
Q3 		$23.9M Sell
1,164,000
-150,000
-11% -$2.7M 7.16% 4
2022
Q2 		$15.2M Hold
1,314,000
– – 6.46% 7
2022
Q1 		$24.3M Hold
1,314,000
– – 9.75% 2
2021
Q4 		$26M Buy
+1,314,000
New +$24.5M 12.16% 2

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

TCG Crossover Management's VRDN Position: Q2 2023 in Review

TCG Crossover Management sold out of Viridian Therapeutics (VRDN) in Q2 2023, closing a stake of 663,610 shares — an estimated $16.9M sold.

TCG Crossover Management first reported a position in VRDN in Q4 2021 and held it in 6 quarters. The position peaked at $28.7M in Q4 2022. 128 funds tracked by Wall St. Rank hold VRDN as of Q2 2023.

  • TCG Crossover Management reported no remaining Viridian Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCG Crossover Management sold 663,610 Viridian Therapeutics shares in Q2 2023, an estimated $16.9M.
  • TCG Crossover Management first reported a position in Viridian Therapeutics in Q4 2021 and held it in 6 quarters.
  • TCG Crossover Management's Viridian Therapeutics position peaked at $28.7M in Q4 2022.
  • 128 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2023.

Based on TCG Crossover Management's 13F filing for Q2 2023, filed 14 Aug 2023.